These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37167718)

  • 41. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
    Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
    Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of the ATPase activity of human ATP-binding cassette transporter-2 (ABCA2).
    Beljanski V; Soulika A; Tucker JM; Townsend DM; Davis W; Tew KD
    In Vivo; 2005; 19(4):657-60. PubMed ID: 15999530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The ATP-Binding Cassette Transporter-2 (ABCA2) Overexpression Modulates Sphingosine Levels and Transcription of the Amyloid Precursor Protein (APP) Gene.
    Davis W
    Curr Alzheimer Res; 2015; 12(9):847-59. PubMed ID: 26510981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
    Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo.
    Lu ZN; Shi ZY; Dang YF; Cheng YN; Guan YH; Hao ZJ; Tian B; He HW; Guo XL
    Biomed Pharmacother; 2019 Dec; 120():109478. PubMed ID: 31568987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System.
    Han X; Liu M; Wang S; Lv G; Ma L; Zeng C; Shi Y
    Curr Cancer Drug Targets; 2015; 15(5):423-34. PubMed ID: 25877381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
    Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
    Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Restoration of circPSMC3 sensitizes gefitinib-resistant esophageal squamous cell carcinoma cells to gefitinib by regulating miR-10a-5p/PTEN axis.
    Zhu H; Du F; Cao C
    Cell Biol Int; 2021 Jan; 45(1):107-116. PubMed ID: 32997362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
    Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
    J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.
    Van Der Steen N; Keller K; Dekker H; Porcelli L; Honeywell RJ; Van Meerloo J; Musters RJP; Kathmann I; Frampton AE; Liu DSK; Ruijtenbeek R; Rolfo C; Pauwels P; Giovannetti E; Peters GJ
    J Cell Physiol; 2020 Nov; 235(11):8085-8097. PubMed ID: 31960422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.
    Zhao XQ; Xie JD; Chen XG; Sim HM; Zhang X; Liang YJ; Singh S; Talele TT; Sun Y; Ambudkar SV; Chen ZS; Fu LW
    Mol Pharmacol; 2012 Jul; 82(1):47-58. PubMed ID: 22491935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2).
    Vulevic B; Chen Z; Boyd JT; Davis W; Walsh ES; Belinsky MG; Tew KD
    Cancer Res; 2001 Apr; 61(8):3339-47. PubMed ID: 11309290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
    Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
    Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ABCA2 as a therapeutic target in cancer and nervous system disorders.
    Mack JT; Brown CB; Tew KD
    Expert Opin Ther Targets; 2008 Apr; 12(4):491-504. PubMed ID: 18348684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.